tsefalen 1000 mg tabletti, kalvopäällysteinen
i.c.f. srl industria chimica fine - cefalexin monohydrate - tabletti, kalvopäällysteinen - 1000 mg - kefaleksiini
refero 550 mg tabletti, kalvopäällysteinen
alfasigma s.p.a. - rifaximinum - tabletti, kalvopäällysteinen - 550 mg - rifaksimiini
menjugate 10 mikrog / 0.5 ml injektioneste, suspensio
glaxosmithkline vaccines s.r.l - neisseria meningitidis-c oligosaccharide, kurkkumätä konjugaatti - injektioneste, suspensio - 10 mikrog / 0.5 ml - meningokokkibakteeri c, puhdistettu polysakkaridi antigeeniin konjugoitu
menjugate 10 mikrog / 0.5 ml injektioneste, suspensio, esitäytetty ruisku
glaxosmithkline vaccines s.r.l - neisseria meningitidis-c oligosaccharide, kurkkumätä konjugaatti - injektioneste, suspensio, esitäytetty ruisku - 10 mikrog / 0.5 ml - meningokokkibakteeri c, puhdistettu polysakkaridi antigeeniin konjugoitu
pronestesic vet 40 mg/ml + 0.036 mg/ml injektioneste, liuos
fatro s.p.a. - adrenaline tartrate, procaine hydrochloride - injektioneste, liuos - 40 mg/ml + 0.036 mg/ml - prokaiinia sisältävät yhdistelmävalmisteet
ertapenem fresenius kabi 1 g kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos
fresenius kabi ab - ertapenem sodium - kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos - 1 g - ertapeneemi
monurelle 3 g rakeet oraaliliuosta varten, annospussi
zambon s.p.a. - fosfomycine trometamol - rakeet oraaliliuosta varten, annospussi - 3 g - fosfomysiini
dalmaprost vet 0.075 mg/ml injektioneste, liuos
fatro s.p.a. - dextrocloprostenol sodium - injektioneste, liuos - 0.075 mg/ml - kloprostenoli
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.
tsefalen 50 mg/ml jauhe oraalisuspensiota varten
i.c.f. srl industria chimica fine - cefalexin monohydrate - jauhe oraalisuspensiota varten - 50 mg/ml - kefaleksiini